🛠️Issues in Transplantation Medicine

One of the biggest problems in transplant medicine is the need for more organs and cells to be transplanted, as well as the shortage of donors in the first place. A few examples of specific transplant sites, such as the heart. In some cases, such as bone marrow transplants for leukaemia, the patient dies before a donor appears. Against this backdrop 1981, Martin Evans of Cambridge University in England created the world's first ES cells. Finally, 17 years later, in 1998, James Thomson of the University of Wisconsin, USA, established a human ES cell line. Although ES cells were expected to be a trump card for regenerative medicine, they have never been clinically tested because of the need for eggs for each patient and the ethical problem that they could lead to the birth of a cloned human being. However, in 2006, Professor Shinya Yamanaka of Kyoto University announced that he had succeeded in creating mouse iPS cells. A year later, Professor Yamanaka and a U.S. research team succeeded in creating human iPS cells in an almost identical fashion. These iPS cells have the advantage of avoiding rejection and ethical issues and have attracted a great deal of attention.

As we have mentioned, the current reality is that producing clinical-grade (medical-use) cells, including iPS cells, is time-consuming, expensive, and extremely difficult to mass-produce.

We have succeeded in developing a technology to automate the process of producing iPS cells using advanced engineering technology, and we are now working on developing a new technology to produce iPS cells.

Problems with iPS Cells

• The requirements for safety checks are demanding

• It is challenging to establish technology to produce high-quality cells stably

• There are some barriers to developing production facilities

Solutions

This project develops an integrated platform and token ecosystem so individuals, research institutions, and medical institutions can access the necessary data and funds to establish production technologies.

The technology developed then will enable medical iPS cell production at an inexpensive cost. With the iPS cells, we aim for services such as transplantation therapies for various diseases and medical insurance.